🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Patient will turn 100 in a few weeks. She has genetically confirmed FH and no clinical ASCVD. My search for resilience genes such as Klotho, IL-6, ACE, CETP or FOXO3 have not panned out. Other suggestions for protective genes?

48 yo male presents with LDL > 350mg/dl and Xanthelesmas. His "FH was cured after stopping the Carnivore diet and xanthelesmas are resolving. Now on a statin due to CAC score of 355. We need to warn people about the potential harm of the carnivore diet.

My biotech TV interview about the history of New Amsterdam Pharma and Obicetrapib eur01.safelinks.protection.outlook.com/?url=https%3A%…

podcasters.spotify.com/pod/show/ellio… Listen to a incredible podcast of my primary care physician brother, Elliott interviewing my son, Preventive Cardiologist David. I am a very proud brother and father

We’ve met the enrollment target in our pivotal Phase 3 PREVAIL CVOT and, driven by strong interest globally, expect to randomize more than 9,000 patients with a history of ASCVD. bit.ly/3TTqpAs

LDL-p vs ApoB. Both outperform LDL-c and perhaps non-HDL-c in risk assessment especially on statins. Although, I am big fan of ApoB, I often prefer LDL-p because discordance from LDL-c is more evident. This is a good example in a patient with premature ASCVD on a statin.

Thanks for all the feedback. Yes insulin resistance (IR) is the main driver behind LDL-c vs LDL-p discordance but also apoB vs LDL-p discordance ( see attached by the iconic Tom Dayspring)In the setting of IR, I recommend low carb diets. Keto may work but in susceptible patients

As a medical school professor, I spoke yesterday at a #upenn session with President, Provost and others. Here is what I said, a plea to American academia on behalf of Jewish students, staff and faculty. #israel #HateSpeech #Zionism #AcademicTwitter

We’re excited to kick off our R&D Day event this morning. Investors are invited to join our live webcast to learn more about our science and commercialization plans, and to hear cardiologists discuss how new oral lipid-lowering therapies could change patient care.

Two conferences, two continents, one growing team and one goal: To share new research on our investigational CETP inhibitor. Thank you to everyone at #NLASessions for another outstanding lipid-focused event.

The Prevention World lost a giant. George Bakris was the most prolific researcher, teacher and clinician in the history of hypertension. He will live on through his great work. I will remember him most as a great friend and colleague who was always eager to help with his amazing

My first patient with serial CLEERLYs following two years of Repatha. With excellent control of LDL-C and a reduction in Lp(a) there is a marked decrease in non-calcified plaque volume and an increase in calcified plaque. The patient is happy and so is his interventional

Thank you to the hundreds of patients and investigators across ten countries who participated in our Phase 3 BROOKLYN trial. Your support moves us closer to our goal of helping people at risk for cardiovascular disease. bit.ly/4fk9iSn

Before and after xanthoma regression in a patient with the Lebanese FH mutation. Interventional lipidology works much better than plastic surgery.

nytimes.com/2023/07/27/hea… This is the obituary in the NYT of the 117 year old women with the loss of function CETP variant identified in the Bronx Aging Study

My Lipid Legend Podcast on Healio. I enjoy working with my longterm friend Ron Corderio. healio.com/cme/mededtalks…

Excited and proud of the Obicetrapib BROOKLYN trial in patients with HeFH as a late breaker at AHA. Thanks Steve Nicholls for an awesome presentation

My first patient to start olezarsen ( anti-apoC3 ASO). She is LPL - Heterozygous but also has two ApoA5 SNPs. She has had at least 10 episodes of pancreatitis in the past 2 years and severe eruptive xanthomas despite weekly plasmapheresis. Hoping for a new lease on life!

Saddened to hear the news of the passing of one of my hero's, Scott Grundy MD PhD. Scott was a pioneer in the burgeoning field of Lipidology, a influential researcher of both nutrition and pharmaceuticals, a great teacher and leader of the national cholesterol guidelines along

ir.newamsterdampharma.com/news-releases/…